Targeted Delivery of Chloroquine to Antigen-Presenting Cells Enhances Inhibition of the Type I Interferon Response
Open Access
- 23 November 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 7 (12) , 5666-5677
Abstract
Systemic lupus erythematosus (SLE) causes damaging inflammation in multiple organs via the accumulation of immune complexes. These complexes activate plasmacytoid dendritic cells (pDCs) via toll-like receptors (TLRs), contributing to disease pathogenesis by driving the secretion of inflammatory type I interferons (IFNs). Antimalarial drugs, such as chloroquine (CQ), are TLR antagonists used to alleviate inflammation in SLE. However, they require ∼3 months of continuous use before achieving therapeutic efficacy and can accumulate in the retinal pigment epithelium with chronic use, resulting in retinopathy. We hypothesized that poly(ethylene glycol)-b-poly(propylene sulfide) filamentous nanocarriers, filomicelles (FMs), could directly deliver CQ to pDCs via passive, morphology-based targeting to concentrate drug delivery to specific immune cells, improve drug activity by increased inhibition of type I IFN, and enhance efficacy per dose. Healthy human peripheral blood mononuclear cells were treated with soluble CQ or CQ-loaded FMs, stimulated with TLR agonists or SLE patient sera, and type I IFN secretion was quantified via multi-subtype IFN-α ELISA and MX1 gene expression using real-time reverse transcription-quantitative polymerase chain reaction. Our results showed that 50 μg CQ/mg FM decreased MX1 expression and IFN-α production after TLR activation with either synthetic nucleic acid agonists or immune complex-rich sera from SLE patients. Cellular uptake and biodistribution studies showed that FMs preferentially accumulate in human pDCs and monocytes in vitro and in tissues frequently damaged in SLE patients (i.e., kidneys), while sparing the eye in vivo. These results showed that nanocarrier morphology enables drug delivery, and CQ-FMs may be equally effective and more targeted than soluble CQ at inhibiting SLE-relevant pathways.Keywords
All Related Versions
Funding Information
- U.S. Department of Veterans Affairs (CX000649-01A1)
- Lupus Foundation of America (Gina M Finzi Memorial Student Summer Fellowship)
- National Institute of General Medical Sciences (R25-GM55036)
- National Science Foundation (1500511)
- Maryland Innovation Initiative (0719-009)
- University of Maryland Baltimore County (Technology Catalyst Fund)
This publication has 89 references indexed in Scilit:
- Production of Interferon α by Human Immunodeficiency Virus Type 1 in Human Plasmacytoid Dendritic Cells Is Dependent on Induction of AutophagyThe Journal of Infectious Diseases, 2012
- The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticlesBiomaterials, 2011
- Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA–Peptide Complexes in Systemic Lupus ErythematosusScience Translational Medicine, 2011
- Network analysis of associations between serum interferon‐α activity, autoantibodies, and clinical features in systemic lupus erythematosusArthritis & Rheumatism, 2010
- Interferon‐α accelerates murine systemic lupus erythematosus in a T cell–dependent mannerArthritis & Rheumatism, 2010
- Chloroquine Modulates HIV-1-Induced Plasmacytoid Dendritic Cell Alpha Interferon: Implication for T-Cell ActivationAntimicrobial Agents and Chemotherapy, 2010
- Induction of autoimmunity by pristane and other naturally occurring hydrocarbonsTrends in Immunology, 2009
- Factors Affecting the Clearance and Biodistribution of Polymeric NanoparticlesMolecular Pharmaceutics, 2008
- Shape effects of filaments versus spherical particles in flow and drug deliveryNature Nanotechnology, 2007
- Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticlesProceedings of the National Academy of Sciences, 2007